FEATURED: MYGN Stock Analysis with Charles Duncan Part 1

You are Watching:

Myriad Genetics, Unique Hybrid Business Model, $48 to $87 Share Price?

The story of Myriad Genetics (MYGN) resonated in the investor community as disappointing Phase 3 data was followed by a 40% stock price increase (from $48 on June 27 to $66 on August 20th, day of this interview). Charles Duncan has the longest formal coverage on Myriad. He explains the rationale behind this development, and the $87 price target he has set for the company shares. Charles and Daniel review Myriads personalized medicine and drug development hybrid business model, and their prospects for growth as standalone companies. Would spinning of the drug development business further unlock shareholder value? Following increased revenues and a recent $100M licensing with Lundbeck, Myriads cash position is quite favorable. Will it acquire? Or could it be acquired?

This interview was conducted at the NASDAQ Marketsite, on August 20th, 2008, in New York City.

Featuring: * Charles Duncan, Managing Director and Senior Biotechnology Analyst, JMP Securities * Daniel Teper, Managing Director at Bionest Partners, and Founder & Chairman of BioBusiness.TV

DISCLAIMER:
BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

Category:

Science & Technology

Tags:

• Charles
• Duncan
• Myriad
• Genetics
• stock